HC Wainwright Has Optimistic Outlook of ARQT FY2027 Earnings

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Investment analysts at HC Wainwright increased their FY2027 EPS estimates for shares of Arcutis Biotherapeutics in a research note issued on Wednesday, February 26th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $1.12 for the year, up from their previous forecast of $0.94. HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ FY2028 earnings at $1.82 EPS.

A number of other research analysts also recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and issued a $20.00 price target on shares of Arcutis Biotherapeutics in a research report on Wednesday. Mizuho raised their target price on shares of Arcutis Biotherapeutics from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday. Guggenheim reaffirmed a “buy” rating on shares of Arcutis Biotherapeutics in a report on Monday. Finally, The Goldman Sachs Group increased their price target on Arcutis Biotherapeutics from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Thursday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Arcutis Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $18.00.

Arcutis Biotherapeutics Stock Performance

ARQT stock opened at $12.80 on Friday. The firm has a market cap of $1.50 billion, a P/E ratio of -7.15 and a beta of 1.29. The stock’s 50 day simple moving average is $13.56 and its 200 day simple moving average is $11.43. The company has a current ratio of 2.46, a quick ratio of 2.38 and a debt-to-equity ratio of 0.67. Arcutis Biotherapeutics has a 12-month low of $6.99 and a 12-month high of $16.20.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.19. The firm had revenue of $71.36 million for the quarter, compared to analysts’ expectations of $60.52 million. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%.

Institutional Trading of Arcutis Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ARQT. GF Fund Management CO. LTD. acquired a new position in Arcutis Biotherapeutics during the fourth quarter valued at $34,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Arcutis Biotherapeutics by 1.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 280,100 shares of the company’s stock valued at $3,902,000 after purchasing an additional 3,409 shares during the period. Voloridge Investment Management LLC lifted its position in shares of Arcutis Biotherapeutics by 126.5% in the fourth quarter. Voloridge Investment Management LLC now owns 290,938 shares of the company’s stock worth $4,053,000 after purchasing an additional 162,495 shares in the last quarter. Squarepoint Ops LLC grew its position in Arcutis Biotherapeutics by 67.2% during the fourth quarter. Squarepoint Ops LLC now owns 121,392 shares of the company’s stock valued at $1,691,000 after purchasing an additional 48,769 shares in the last quarter. Finally, Suvretta Capital Management LLC increased its stake in Arcutis Biotherapeutics by 6.3% in the 4th quarter. Suvretta Capital Management LLC now owns 11,399,138 shares of the company’s stock valued at $158,790,000 after buying an additional 677,627 shares during the period.

Insider Activity

In related news, Director Howard G. Welgus sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.67, for a total transaction of $146,700.00. Following the transaction, the director now owns 151,944 shares in the company, valued at $2,229,018.48. This trade represents a 6.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Todd Franklin Watanabe sold 15,000 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $15.17, for a total value of $227,550.00. Following the completion of the sale, the insider now owns 823,430 shares of the company’s stock, valued at approximately $12,491,433.10. This trade represents a 1.79 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 55,029 shares of company stock valued at $756,017. Insiders own 9.50% of the company’s stock.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.